Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Authorizes GI Genius As A Smarter AI-Based Colonoscopy Tool

Executive Summary

According to a large clinical study, the first such device with AI-enabled software is better at detecting potential lesions than traditional colonoscopies and could allow detection of colon cancer sooner.

You may also be interested in...



Minute Insight: Medtronic, Amazon, ASGE Collaborate To Expand Access To Colorectal Cancer Screening

Medtronic’s health equity assistance program for colon cancer screening will donate 50 Medtronic GI Genius endoscopy systems to centers that treat low-income and underserved communities.

Digital Health Roundup, April 2021: Digital Transformation In OR, Clinical Trials, Remote Monitoring

In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from April.

MTI Outlook 2020: Global Health Systems Are Learning To Embrace AI As A Force For Good

The term artificial intelligence was coined at the Dartmouth Summer Research Project in 1956, but it is only in very recent years that it has been consistently at the top of the agenda in discussions on the future direction of health care. AI is now increasingly seen as a realistic solution to demand overload on clinicians. At the same time, techno-fears are abating. This confluence will transform health care radically in the next two decades.  

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT143777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel